Inari Medical, Inc. (NASDAQ:NARI) Shares Sold by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC trimmed its stake in shares of Inari Medical, Inc. (NASDAQ:NARIGet Rating) by 2.4% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 22,841 shares of the company’s stock after selling 570 shares during the period. Janney Montgomery Scott LLC’s holdings in Inari Medical were worth $1,659,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Texas Permanent School Fund acquired a new stake in Inari Medical during the second quarter worth about $1,671,000. State of New Jersey Common Pension Fund D acquired a new stake in Inari Medical during the second quarter worth about $2,652,000. Renaissance Technologies LLC grew its holdings in Inari Medical by 105.6% in the second quarter. Renaissance Technologies LLC now owns 194,299 shares of the company’s stock valued at $13,210,000 after purchasing an additional 99,800 shares during the period. Strs Ohio grew its holdings in Inari Medical by 23.3% in the second quarter. Strs Ohio now owns 5,300 shares of the company’s stock valued at $360,000 after purchasing an additional 1,000 shares during the period. Finally, Brown Advisory Inc. grew its holdings in Inari Medical by 54.9% in the second quarter. Brown Advisory Inc. now owns 1,075,189 shares of the company’s stock valued at $73,197,000 after purchasing an additional 380,961 shares during the period. 85.19% of the stock is owned by institutional investors and hedge funds.

Inari Medical Stock Up 1.8 %

Shares of NARI opened at $67.05 on Monday. Inari Medical, Inc. has a 52-week low of $50.50 and a 52-week high of $100.00. The company has a market capitalization of $3.60 billion, a PE ratio of -159.64 and a beta of 1.21. The stock has a fifty day simple moving average of $70.17 and a two-hundred day simple moving average of $72.73.

Inari Medical (NASDAQ:NARIGet Rating) last issued its earnings results on Wednesday, November 2nd. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.05. Inari Medical had a negative return on equity of 6.02% and a negative net margin of 6.23%. The business had revenue of $96.20 million during the quarter, compared to the consensus estimate of $90.65 million. As a group, equities analysts anticipate that Inari Medical, Inc. will post -0.61 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on NARI shares. Truist Financial dropped their price objective on Inari Medical from $84.00 to $75.00 and set a “hold” rating on the stock in a report on Tuesday, December 20th. Jefferies Financial Group started coverage on Inari Medical in a report on Wednesday, October 12th. They issued a “buy” rating and a $88.00 price objective on the stock. Morgan Stanley dropped their price objective on Inari Medical from $95.00 to $83.00 and set an “overweight” rating on the stock in a report on Friday, January 6th. BTIG Research decreased their target price on Inari Medical from $100.00 to $97.00 and set a “buy” rating on the stock in a research report on Monday, October 17th. Finally, Wells Fargo & Company dropped their price target on Inari Medical from $125.00 to $105.00 in a research report on Thursday, November 3rd. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.60.

Insiders Place Their Bets

In other Inari Medical news, Director Donald B. Milder sold 7,000 shares of the firm’s stock in a transaction on Tuesday, October 18th. The stock was sold at an average price of $80.07, for a total value of $560,490.00. Following the completion of the sale, the director now directly owns 3,192,614 shares of the company’s stock, valued at approximately $255,632,602.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Donald B. Milder sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, October 18th. The stock was sold at an average price of $80.07, for a total transaction of $560,490.00. Following the completion of the sale, the director now directly owns 3,192,614 shares of the company’s stock, valued at approximately $255,632,602.98. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO William Hoffman sold 55,000 shares of the firm’s stock in a transaction dated Tuesday, November 15th. The stock was sold at an average price of $81.67, for a total value of $4,491,850.00. Following the sale, the chief executive officer now directly owns 237,481 shares of the company’s stock, valued at $19,395,073.27. The disclosure for this sale can be found here. Insiders sold 219,250 shares of company stock valued at $16,112,973 in the last three months. 11.90% of the stock is currently owned by insiders.

Inari Medical Profile

(Get Rating)

Inari Medical, Inc, a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism.

Featured Articles

Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. (NASDAQ:NARIGet Rating).

Institutional Ownership by Quarter for Inari Medical (NASDAQ:NARI)

Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.